Synapse-Related Serum and P300 Biomarkers Predict the Occurrence of Mild Cognitive Impairment in Depression

Neuropsychiatr Dis Treat. 2024 Mar 5:20:493-503. doi: 10.2147/NDT.S448312. eCollection 2024.

Abstract

Background: Cognitive impairment is one of the common concomitant symptoms of depression. The aims of the present study were to predict the occurrence of mild cognitive impairment (MCI) in patients with depression.

Methods: In this study, 217 patients with depression were recruited. Demographic data, serum indices and ERP indices from all participants were collected in the baseline period. The participants were followed for one year, and data from 200 patients were included in final analysis. Patients with depression were divided into those with MCI group (DWM group; n=145) and those without MCI (DWOM group; n=55). Data from the DWM group and the DWOM group were used to construct a logistic regression model, and a receiver operating characteristic (ROC) curve was drawn. Another 72 patients were used to validate the accuracy of our model.

Results: Compared with DWOM individuals, DWM individuals were more likely to live alone (P<0.05), had lower baseline serum levels of brain-derived neurotrophic factor (BDNF), fibroblast growth factor 2 (FGF2), and fibroblast growth factor 22 (FGF22) (P<0.05), and exhibited higher baseline latencies of P300, mismatch negativity (MMN), and N200 (P<0.05). Baseline serum BDNF and FGF22 levels, along with the P300 latency, were selected to construct the regression model using logistic regression. The regression equation was [Formula: see text], and the combination of the 3 indices yielded an area under the ROC curve (AUC) of 0.790 and a predictive accuracy of 0.806.

Conclusion: The logistic regression model and ROC curves based on serum BDNF and FGF22 levels and the P300 latency could provide a more effective means to predict the occurrence of MCI in patients with depression.

Keywords: P300; brain-derived neurotrophic factor; depression; fibroblast growth factor 22; mild cognitive impairment; prediction.

Grants and funding

This work was supported by National Natural Science Foundation of China (82101431), Key Project of Medical Research of Jiangsu Provincial Health and Health Commission (ZD2022062), Medical Education Collaborative Innovation Fund of Jiangsu University (No.JDY2023002), Scientific and Technological Innovation Funding Project of Zhenjiang City (SH2022039), Open Project of Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases (202210), Project of Introducing New Technologies for Elderly Health of Jiangsu Provincial Health Commission (LX2021018), Scientific Research Project of Jiangsu Maternal and Child Health Association (FYX202006); Incubation Project of Zhenjiang City Hierarchical Diagnostic and Treatment Innovative Project (2021ZDX07), Scientific Research Project of Zhenjiang City “169 Project”, CSA Cerebrovascular Disease Innovation Medical Research Fund.